|A human type 5 adenovirus–based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity|
F Smaill, M Jeyanathan, M Smieja, MF Medina, N Thanthrige-Don, ...
Science translational medicine 5 (205), 205ra134-205ra134, 2013
|A TTO-derived value set of the EQ-5D-5L for Canada|
JJACEQDLVSG Xie F, Pullenayegum EM, Gaebel K, Bansback N, Bryan S, Ohinmaa A ...
Medical Care, 54 (1), 98, 2016
|Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate?|
EM Pullenayegum, JE Tarride, F Xie, R Goeree, HC Gerstein, D O'Reilly
Value in Health 13 (4), 487-494, 2010
|The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women|
R Hopkins, R Goeree, E Pullenayegum, J Adachi, A Papaioannou, F Xie, ...
BMC musculoskeletal disorders 12 (1), 209, 2011
|Improving the interpretation of quality of life evidence in meta-analyses: the application of minimal important difference units|
BC Johnston, K Thorlund, HJ Schünemann, F Xie, MH Murad, VM Montori, ...
Health and quality of life outcomes 8 (1), 116, 2010
|Cross-cultural adaptation and validation of Singapore English and Chinese versions of the Knee injury and Osteoarthritis Outcome Score (KOOS) in Asians with knee osteoarthritis …|
F Xie, SC Li, EM Roos, KY Fong, NN Lo, SJ Yeo, KY Yang, W Yeo, ...
Osteoarthritis and cartilage 14 (11), 1098-1103, 2006
|Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application|
R Goeree, J He, D O’Reilly, JE Tarride, F Xie, M Lim, N Burke
ClinicoEconomics and outcomes research: CEOR 3, 89, 2011
|The European organization for research and treatment of cancer quality of life questionnaire (EORTC QLQ-C30): validation of english version in singapore|
N Luo, CSL Fones, SE Lim, F Xie, J Thumboo, SC Li
Quality of Life Research 14 (4), 1181-1186, 2005
|Validation of Chinese Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in patients scheduled for total knee replacement|
F Xie, SC Li, R Goeree, JE Tarride, D O’Reilly, NN Lo, SJ Yeo, KY Yang, ...
Quality of Life Research 17 (4), 595, 2008
|Economic and humanistic burden of osteoarthritis: a systematic review of large sample studies|
F Xie, B Kovic, X Jin, X He, M Wang, C Silvestre
Pharmacoeconomics 34 (11), 1087-1100, 2016
|Comparing EQ-5D valuation studies: a systematic review and methodological reporting checklist|
F Xie, K Gaebel, K Perampaladas, B Doble, E Pullenayegum
Medical Decision Making 34 (1), 8-20, 2014
|A review of health utilities across conditions common in paediatric and adult populations|
JE Tarride, N Burke, M Bischof, RB Hopkins, L Goeree, K Campbell, F Xie, ...
Health and quality of life outcomes 8 (1), 12, 2010
|A study on indirect and intangible costs for patients with knee osteoarthritis in Singapore|
F Xie, J Thumboo, KY Fong, NN Lo, SJ Yeo, KY Yang, SC Li
Value in Health 11, S84-S90, 2008
|Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients with severe symptomatic …|
B Doble, G Blackhouse, R Goeree, F Xie
The Journal of thoracic and cardiovascular surgery 146 (1), 52-60. e3, 2013
|Cross-cultural adaptation and validation of Singapore English and Chinese Versions of the Oxford Knee Score (OKS) in knee osteoarthritis patients undergoing total knee replacement|
F Xie, SC Li, NN Lo, SJ Yeo, KY Yang, W Yeo, HC Chong, KY Fong, ...
Osteoarthritis and cartilage 15 (9), 1019-1024, 2007
|Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada|
DJ O’Reilly, F Xie, E Pullenayegum, HC Gerstein, J Greb, GK Blackhouse, ...
Quality of Life Research 20 (6), 939-943, 2011
|Discussing study limitations in reports of biomedical studies-the need for more transparency|
MA Puhan, EA Akl, D Bryant, F Xie, G Apolone, G ter Riet
Health and quality of life outcomes 10 (1), 23, 2012
|A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment|
JE Tarride, R Hopkins, G Blackhouse, JM Bowen, M Bischof, ...
Pharmacoeconomics 28 (4), 255-277, 2010
|Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores|
NS McClure, F Al Sayah, F Xie, N Luo, JA Johnson
Value in Health 20 (4), 644-650, 2017
|Use of a disease-specific instrument in economic evaluations: mapping WOMAC onto the EQ-5D utility index|
F Xie, EM Pullenayegum, SC Li, R Hopkins, J Thumboo, NN Lo
Value in Health 13 (8), 873-878, 2010